What question did this study set out to answer?

Evaluate the effectiveness and safety of venetoclax in relapsed/refractory light-chain amyloidosis patients.

December 8, 2025Blood

Efficacy of venetoclax in the treatment of relapsed/refractory light-chain amyloidosis

View Full Paper

Ask AI

Bookmark

Authors

Single-center trial shows venetoclax improves hematologic response in AL amyloidosis, suggesting high t(11;14) enhances efficacy.

Evaluate the effectiveness and safety of venetoclax in relapsed/refractory light-chain amyloidosis patients.
Retrospective review of AL amyloidosis patients treated with venetoclax-based regimens.
Inclusion of patients who did not achieve very good partial response or progressed after prior therapies.
Assessment of hematologic response, organ response, and adverse events.
Overall hematologic response rate was 93%.
Complete response plus very good partial response was achieved in 79% of patients.
High t(11;14) associated with superior response rates compared to low t(11;14).

Guan et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark